TRC 253

Drug Profile

TRC 253

Alternative Names: JNJ 63576253; TRC253

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; TRACON Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 28 Mar 2017 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02987829)
  • 01 Jan 2017 US FDA approves IND application for TRC 253 in Prostate cancer
  • 28 Sep 2016 TRC 253 licensed to TRACON Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top